303 A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors. (September 2015) - De Weger, V.; Varga, A.; De Jonge, M.; Langenberg, M.; Mergui-Roelvink, M.; Massard, C.; Van der Vlist, A.; Devriese, L.; Goodstal, S.; Zheng, W.; Tuffal, G.; Semiond, D.; et al.